
BeOne Highlights Phase 3 BRUKINSA Data in CLL Patients Aged 80+ at EHA 2026
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit BeOne Medicines Ltd. a global oncology company, announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small…












